CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
Site Search
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
The Compass Resource Database follows the AIRS Standards that require the service to develop, maintain, use, and disseminate an accurate, up-to-date online resource database that contains information about available community resources, including details about the services provided and the conditions under which they are available.
Many people with cystic fibrosis and their families have questions about their rights as an individual living with a disease.
When considering making a change to your health insurance coverage or enrolling in a plan, it is important to know about the annual open enrollment period and when those changes can be made.
Navigating CF is a series of short videos that help people with CF, their families, and care teams navigate complex issues. No matter where you are on your journey, Navigating CF can help.
The Cystic Fibrosis Foundation, alongside the CF community, urges Congress to pass the PASTEUR Act and the HELP Copays Act.